HQL (abrdn Life Sciences Investors) Asset Impairment Charge: $0.0 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HQL abrdn Life Sciences Investors HQL
51 GF Score
Price $20.96
GF Value $62.01
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is abrdn Life Sciences Investors Asset Impairment Charge?

abrdn Life Sciences Investors HQL -2.74% 51 Asset Impairment Charge is $0.0 Mil as of Mar. 2026. GuruFocus rates HQL with a GF Score™ of 51/100 and a GF Value™ of $62.01 (Significantly Undervalued). The stock has 4 warning signs investors should review.

abrdn Life Sciences Investors's Asset Impairment Charge for the six months ended in Mar. 2026 was $0.0 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Mar. 2026 was $0.0 Mil.

abrdn Life Sciences Investors Asset Impairment Charge Related Terms

abrdn Life Sciences Investors Asset Impairment Charge Historical Data

* Premium members only.

The historical data trend for abrdn Life Sciences Investors's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

abrdn Life Sciences Investors Asset Impairment Charge Chart

abrdn Life Sciences Investors Annual Data
Trend Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Asset Impairment Charge
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

abrdn Life Sciences Investors Semi-Annual Data
Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Asset Impairment Charge Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
HQL
51GF Score
abrdn Life Sciences Investors HQL
Asset Impairment Charge is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

abrdn Life Sciences Investors Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.0 Mil.

What does a Asset Impairment Charge of $0.0 Mil mean?
abrdn Life Sciences Investors (HQL) has a Asset Impairment Charge of $0.0 Mil as of Mar. 2026.
Is abrdn Life Sciences Investors' Asset Impairment Charge too high?
abrdn Life Sciences Investors' current Asset Impairment Charge is $0.0 Mil. Overall, abrdn Life Sciences Investors has a GF Score™ of 51/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does abrdn Life Sciences Investors' Asset Impairment Charge compare to MUJ and ACP?
abrdn Life Sciences Investors' Asset Impairment Charge of $0.0 Mil can be compared against companies in the Asset Management industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Asset Impairment Charge for an Asset Management company?
A good Asset Impairment Charge depends on the Asset Management industry context. However, Asset Impairment Charge should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Asset Impairment Charge mean?
A high Asset Impairment Charge can signal that a stock is expensive relative to its fundamentals. abrdn Life Sciences Investors's current Asset Impairment Charge is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is abrdn Life Sciences Investors stock overvalued right now?
Based on GuruFocus' analysis, abrdn Life Sciences Investors (HQL) is currently considered Significantly Undervalued. The stock's GF Value™ is $62.01, compared to a current price of $20.96 — trading 66.2% below its estimated fair value. The current Asset Impairment Charge is $0.0 Mil. abrdn Life Sciences Investors' overall GF Score™ is 51/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Asset Impairment Charge calculated?
Asset Impairment Charge is calculated from a company's financial statements. For abrdn Life Sciences Investors (HQL), the current Asset Impairment Charge is $0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is abrdn Life Sciences Investors (HQL) Overvalued in 2026?

Based on GuruFocus' analysis, abrdn Life Sciences Investors stock appears to be undervalued. The current stock price of $20.96 is trading 66.2% below its estimated GF Value™ of $62.01. GuruFocus considers abrdn Life Sciences Investors to be Significantly Undervalued.

Key valuation signals for HQL:

  • Asset Impairment Charge: $0.0 Mil
  • GF Value™: $62.01 vs. price of $20.96 (66.2% below fair value)
  • GF Score™: 51/100 with 4 warning signs

No single metric tells the full story. See the HQL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

abrdn Life Sciences Investors Business Description

Address 1900 Market Street, Suite 200, Philadelphia, PA, USA, 19103
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mainly in securities of life sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser to have the potential for above-average growth.
51GF Score

Get the complete analysis for HQL

Asset Impairment Charge is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$20.96
Price
$62.01
GF Value